Relypsa Lost Major Ground; Feuerstein Tweets Favus Report Said 'Nothing New'
Shares Of Relypsa Hit Hard Following New Employment Inducement Grants, Confidential Treatment Order
Report: AstraZeneca Eyes Acquisition Of Relypsa For $46 Per Share
EXCLUSIVE: Relypsa Being Evaluated By 3-4 Potential Acquirers; Sanofi Seen As 'Natural Buyer'